August 2023 in “Dermatology and Therapy” This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.
July 2023 in “Clinical and Experimental Dermatology” In this study, combining baricitinib and prednisone effectively achieved complete hair regrowth in seven out of eight women with very severe alopecia areata, contrasting with less effective results from each drug used alone.
48 citations
,
July 2023 in “Pediatric Dermatology” This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.
12 citations
,
June 2023 in “JAMA network open” In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.
4 citations
,
June 2023 in “Frontiers in immunology” This study found that JAK inhibitors effectively improve alopecia areata outcomes, as indicated by SALT scores, but they were associated with an increased risk of adverse effects, with 921 out of 1508 patients experiencing adverse reactions.
2 citations
,
June 2023 in “Skin Research and Technology” This study reviewed 39 studies with 3204 patients to identify characteristic trichoscopic findings in alopecia areata, highlighting yellow and black dots, broken, short vellus, and tapering hairs as key indicators. It found no single diagnostic trichoscopic finding but observed trichoscopy's utility in monitoring treatment response.
3 citations
,
May 2023 in “Clinical drug investigation” This study reviewed the safety of JAK inhibitors for alopecia areata, finding that common side effects included headache and acne, with varying risks for respiratory infections and no increased risk of serious adverse events.
7 citations
,
April 2023 in “Frontiers in immunology” This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
10 citations
,
January 2023 in “Journal of the European Academy of Dermatology and Venereology” This review highlights the significant negative impact of alopecia areata on quality of life, mental health, and work, calling for individualized approaches and effective treatments to mitigate these effects.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.
January 2023 in “Przegla̧d dermatologiczny” There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.
34 citations
,
November 2022 in “Clinical and Experimental Dermatology” This study found that individuals with AA have a higher incidence of atopic and autoimmune conditions, suggesting both Th1 and Th2 immune responses may play a role in its development.
1 citations
,
August 2022 in “JAAD case reports” This article discusses the patterns and variants of alopecia areata, including the rare sisaipho, but reports no new research findings.
8 citations
,
June 2022 in “Frontiers in Medicine” This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.
148 citations
,
March 2022 in “The New England Journal of Medicine” In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.
11 citations
,
January 2022 in “Journal der Deutschen Dermatologischen Gesellschaft” This review discusses current and emerging therapies for alopecia areata, highlights the challenges in managing this chronic disease, and emphasizes the importance of addressing its psychosocial impacts; it reports no new clinical results.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.
12 citations
,
August 2020 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study found that most chronic alopecia areata patients treated with azathioprine, methotrexate, or cyclosporine continued treatment for at least 12 months, often requiring concurrent low-dose prednisolone.
13 citations
,
April 2020 in “Dermatology and therapy” This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.
19 citations
,
July 2019 in “Journal of Cosmetic Dermatology” This study found that in patients with patchy alopecia areata, certain trichoscopic features like upright regrowing hairs and pigtail hairs are positive predictive markers for treatment success.
95 citations
,
November 2018 in “Australasian journal of dermatology” This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.
89 citations
,
March 2018 in “The Journal of Dermatology” This review presents various trichoscopic findings for diagnosing alopecia areata but reports no new clinical results, emphasizing that no single marker is pathognomonic and multiple features should be considered together.
99 citations
,
July 2017 in “Clinical Reviews in Allergy & Immunology” This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.
22 citations
,
June 2017 in “Journal of dermatological treatment” This case series observed that 57% of pediatric patients with alopecia areata experienced significant hair regrowth with methotrexate treatment, which was generally safe, although some results were inconclusive due to follow-up issues.
7 citations
,
January 2017 in “Dermatology” In this study, late-onset alopecia areata in Israeli patients was predominantly observed in females with mild disease, showing a high rate of complete hair regrowth but frequent relapses.
31 citations
,
April 2016 in “Journal of the American Academy of Dermatology” Oral dexamethasone may help regrow hair in adults with alopecia totalis and universalis.
28 citations
,
January 2016 in “Dermatology” This study observed that methotrexate combined with low- to moderate-dose oral corticosteroids may effectively treat severe alopecia areata, though long-term maintenance is often necessary due to relapse after tapering.
44 citations
,
August 2014 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This study found that methotrexate may be an effective and safe treatment option for severe alopecia areata, with better regrowth results when combined with corticosteroids.
85 citations
,
October 2012 in “Dermatologic Clinics” This article reviews recent updates on alopecia areata, focusing on its causes, clinical presentation, and treatment options, and provides treatment plans by patient age and disease extent, but reports no new clinical results.
70 citations
,
April 2011 in “British journal of dermatology/British journal of dermatology, Supplement” This retrospective study found that methotrexate had variable efficacy in treating severe alopecia areata in children, with successful hair regrowth observed in five out of thirteen assessable cases.
141 citations
,
February 2005 in “Journal of the American Academy of Dermatology” In this study, oral prednisolone pulse therapy led to significant hair regrowth in some patients with extensive alopecia areata, whereas no improvement was seen in the placebo group.
